Letter

Colorectal cancer

Limitations of trial

BMJ 2009; 338 doi: 10.1136/bmj.b2531 (Published 23 June 2009)
Cite this as: BMJ 2009;338:b2531

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Richard Peto, professor of medical statistics and epidemiology1
  1. 1University of Oxford, Oxford OX3 7LF
  1. richard.peto{at}ctsu.ox.ac.uk

    In the NORCCAP trial of colorectal cancer screening in Norway,1 the number of patients screened and the range of intestinal sites examined was too limited for even an apparent fourfold reduction in mortality from rectosigmoid cancer to be reliably detectable by a standard intention-to-treat analysis of overall colorectal cancer mortality. In these circumstances, it seems …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular